Latest news with #Roche Holding AG
Bloomberg
5 days ago
- Business
- Bloomberg
Roche May Sell Drugs Directly to US Patients to Bypass Middlemen
Roche Holding AG is weighing direct-to-patient drug sales in the US, bypassing the middleman for its pricey medicines for multiple sclerosis, eye disease and cancer. The Swiss drugmaker has discussed direct-to-patient sales with the US government, Chief Executive Officer Thomas Schinecker said on Thursday as the company reported quarterly earnings. The move would bring down costs 'quite quickly,' he said.
Bloomberg
6 days ago
- Business
- Bloomberg
Roche First-Half Earnings Beat Estimates on Asthma, Eye Drugs
Roche Holding AG said first-half profit advanced, helped by sales of medicines for asthma, eye disease and multiple sclerosis. Earnings per share excluding some items climbed 8% to 11.08 Swiss francs ($13.98), the drugmaker said Thursday. That beat the average estimate of analysts surveyed by Bloomberg.
Bloomberg
7 days ago
- Business
- Bloomberg
Roche Pauses Shipments of Contested Gene Therapy Outside the US
Roche Holding AG paused all shipments of the controversial gene therapy Elevidys following a similar action by the embattled US biotechnology company that developed the treatment. The Swiss drugmaker said the pause effective today applies to new orders of Elevidys in countries outside the U.S. that base their approvals off Food and Drug Administration decisions. It covers all patients with Duchenne muscular dystrophy regardless of their ability to walk. It's voluntary and temporary, the company said in an emailed statement.
Globe and Mail
19-07-2025
- Business
- Globe and Mail
Berenberg Bank Remains a Hold on Roche Holding AG (RHHVF)
In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Roche Holding AG, with a price target of CHF290.00. The company's shares closed yesterday at $320.35. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Holford covers the Healthcare sector, focusing on stocks such as Novartis AG, GlaxoSmithKline, and GlaxoSmithKline. According to TipRanks, Holford has an average return of 11.9% and a 62.65% success rate on recommended stocks. In addition to Berenberg Bank, Roche Holding AG also received a Hold from Barclays's Emily Field in a report issued on July 16. However, on July 14, J.P. Morgan maintained a Sell rating on Roche Holding AG (Other OTC: RHHVF). The company has a one-year high of $354.19 and a one-year low of $269.80. Currently, Roche Holding AG has an average volume of 11.8K.
